The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market
In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimilar, Herzuma, from the UK market.
In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimilar, Herzuma, from the UK market.
What's Your Reaction?
